On November 5, 2026 Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, reported that it will be presenting at BIO-Europe 2026, being held on November 9-11, 2026, in Cologne, Germany.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Faisal Mehmud, Chief Medical Officer of Medicus, presentation will highlight the Company’s progress around precision oncology, anchored by CD228V, an investigational antibody-drug conjugate (ADC) molecule utilizing an established vedotin linker-payload platform, as well as SkinJect, an investigational localized immuno-oncology precision product, for multiple basal cell carcinoma lesions in patients with Gorlin syndrome, a rare autosomal dominant genetic disease. The presentation will also cover development and partnership outlook for the Teverelix Program.
Presentation details:
Date: Monday, November 9, 2026
Time: 9:15 to 9:30 a.m. CET
Location: Theatre B, Koelnmesse, Cologne, Germany
Dr. Mehmud will be available to hold one-on-one meetings with institutional investors and prospective partners throughout the conference. The full BIO-Europe 2026 agenda is available on the conference website.
Advancing a Focused Precision Oncology Portfolio
CD228V is an early clinical-stage ADC, utilizing Pfizer’s established vedotin linker-payload platform. Medicus is prioritizing clinical proof-of-concept in melanoma, particularly relapsed, refractory or immunotherapy-resistant disease, with biomarker research intended to guide further development. The Company believes that evidence generated in melanoma could support evaluation in additional CD228-expressing solid tumors.
Medicus aims to build clinical evidence in defined patient populations while pursuing partnerships that can contribute expertise and development resources.
(Press release, Medicus Pharma, NOV 5, 2026, View Source [SID1234674317])